

# Noel T Southall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9336393/publications.pdf>

Version: 2024-02-01

165  
papers

10,676  
citations

50566

48  
h-index

43601

95  
g-index

173  
all docs

173  
docs citations

173  
times ranked

18535  
citing authors

#	ARTICLE	IF	CITATIONS
1	NCATS Inxight Drugs: a comprehensive and curated portal for translational research. <i>Nucleic Acids Research</i> , 2022, 50, D1307-D1316.	6.5	16
2	Discovery of a functionally selective ghrelin receptor (GHSR <sub>1a</sub> ) ligand for modulating brain dopamine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2112397119.	3.3	4
3	Progress toward a universal biomedical data translator. <i>Clinical and Translational Science</i> , 2022, 15, 1838-1847.	1.5	17
4	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8303-8331.	2.9	4
5	Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science. <i>Clinical and Translational Science</i> , 2022, 15, 1848-1855.	1.5	38
6	TCRD and Pharos 2021: mining the human proteome for disease biology. <i>Nucleic Acids Research</i> , 2021, 49, D1334-D1346.	6.5	109
7	Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9431-9443.	2.9	2
8	Validating ADME QSAR Models Using Marketed Drugs. <i>SLAS Discovery</i> , 2021, 26, 1326-1336.	1.4	16
9	Identification of Small Molecule Inhibitors of a Mir155 Transcriptional Reporter in Th17 Cells. <i>Scientific Reports</i> , 2021, 11, 11498.	1.6	2
10	Global Substance Registration System: consistent scientific descriptions for substances related to health. <i>Nucleic Acids Research</i> , 2021, 49, D1179-D1185.	6.5	12
11	How to Illuminate the Druggable Genome Using Pharos. <i>Current Protocols in Bioinformatics</i> , 2020, 69, e92.	25.8	33
12	Critical Assessment of Artificial Intelligence Methods for Prediction of hERG Channel Inhibition in the "Big Data" Era. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 6007-6019.	2.5	29
13	Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. <i>Nature Microbiology</i> , 2020, 5, 1532-1541.	5.9	10
14	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. <i>Scientific Reports</i> , 2020, 10, 20713.	1.6	23
15	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. <i>Cell Chemical Biology</i> , 2020, 27, 780-792.e5.	2.5	18
16	Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding. <i>Communications Biology</i> , 2020, 3, 109.	2.0	29
17	Validation and Characterization of Five Distinct Novel Inhibitors of Human Cytomegalovirus. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3896-3907.	2.9	8
18	Evaluating kratom alkaloids using PHASE. <i>PLoS ONE</i> , 2020, 15, e0229646.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Anxiolytic Drug FGIN-1-27 Ameliorates Autoimmunity by Metabolic Reprogramming of Pathogenic Th17 Cells. <i>Scientific Reports</i> , 2020, 10, 3766.	1.6	10
20	Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. <i>Science Advances</i> , 2020, 6, eaaz2736.	4.7	31
21	Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis. <i>Cancer Research</i> , 2020, 80, 2689-2702.	0.4	24
22	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D <sub>3</sub> Dopamine Receptor Agonist. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5526-5567.	2.9	15
23	Predicting liver cytosol stability of small molecules. <i>Journal of Cheminformatics</i> , 2020, 12, 21.	2.8	16
24	Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. <i>Scientific Reports</i> , 2020, 10, 5688.	1.6	7
25	Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
26	Advancing precision medicine with personalized drug screening. <i>Drug Discovery Today</i> , 2019, 24, 272-278.	3.2	27
27	Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. <i>FASEB Journal</i> , 2019, 33, 12435-12446.	0.2	18
28	The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 225.	1.2	19
29	Novel Consensus Architecture To Improve Performance of Large-Scale Multitask Deep Learning QSAR Models. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 4613-4624.	2.5	47
30	A large scale high-throughput screen identifies chemical inhibitors of phosphatidylinositol 4-kinase type II alpha. <i>Journal of Lipid Research</i> , 2019, 60, 683-693.	2.0	16
31	Freedom of Information Act Access to an Investigational New Drug Application. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 497-500.	2.5	2
32	The NCATS Pharmaceutical Collection: a 10-year update. <i>Drug Discovery Today</i> , 2019, 24, 2341-2349.	3.2	48
33	Deconstructing the Translational Tower of Babel. <i>Clinical and Translational Science</i> , 2019, 12, 85-85.	1.5	17
34	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. <i>Antiviral Research</i> , 2019, 163, 149-155.	1.9	6
35	The NCATS BioPlanet – An Integrated Platform for Exploring the Universe of Cellular Signaling Pathways for Toxicology, Systems Biology, and Chemical Genomics. <i>Frontiers in Pharmacology</i> , 2019, 10, 445.	1.6	179
36	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1113-1119.	1.0	14

#	ARTICLE	IF	CITATIONS
37	Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy. <i>Human Molecular Genetics</i> , 2019, 28, 2120-2132.	1.4	14
38	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. <i>Cell Chemical Biology</i> , 2019, 26, 244-254.e4.	2.5	25
39	Agonist-specific voltage-dependent gating of lysosomal two-pore Na <sup>+</sup> channels. <i>ELife</i> , 2019, 8, .	2.8	32
40	Unexplored therapeutic opportunities in the human genome. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 317-332.	21.5	263
41	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. <i>Oncogene</i> , 2018, 37, 3981-3997.	2.6	31
42	Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 38-45.	1.3	14
43	DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. <i>Scientific Reports</i> , 2018, 8, 17715.	1.6	41
44	Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1067-1080.	1.1	9
45	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	55
46	High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. <i>Scientific Reports</i> , 2018, 8, 8161.	1.6	199
47	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 79-92.	2.6	9
48	Identification of Positive Allosteric Modulators of the D <sub>1</sub> Dopamine Receptor That Act at Diverse Binding Sites. <i>Molecular Pharmacology</i> , 2018, 94, 1197-1209.	1.0	35
49	Pharos: Collating protein information to shed light on the druggable genome. <i>Nucleic Acids Research</i> , 2017, 45, D995-D1002.	6.5	271
50	SU9516 Increases $\alpha$ 2 $\beta$ 1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy. <i>Molecular Therapy</i> , 2017, 25, 1395-1407.	3.7	21
51	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6364-6383.	2.9	12
52	Prediction of hERG Liability " Using SVM Classification, Bootstrapping and Jackknifing. <i>Molecular Informatics</i> , 2017, 36, 1600126.	1.4	35
53	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. <i>Scientific Reports</i> , 2017, 7, 11673.	1.6	5
54	Inhibition of PIP4K <sup>3</sup> ameliorates the pathological effects of mutant huntingtin protein. <i>ELife</i> , 2017, 6, .	2.8	49

#	ARTICLE	IF	CITATIONS
55	A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration. <i>Scientific Reports</i> , 2016, 6, 22273.	1.6	15
56	High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress. <i>Stem Cells Translational Medicine</i> , 2016, 5, 613-627.	1.6	31
57	Kinetic, Mutational, and Structural Studies of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease. <i>Biochemistry</i> , 2016, 55, 3007-3019.	1.2	25
58	Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease. <i>Journal of Neuroscience Research</i> , 2016, 94, 1231-1245.	1.3	2
59	Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-11.	3.0	59
60	High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. <i>Scientific Reports</i> , 2016, 6, 34060.	1.6	20
61	Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6204-6216.	3.2	49
62	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 426-441.	2.4	34
63	Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. <i>Biochemistry</i> , 2016, 55, 1772-1783.	1.2	22
64	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 841-853.	2.9	30
65	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. <i>JCI Insight</i> , 2016, 1, e88427.	2.3	16
66	Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus. <i>PLoS Pathogens</i> , 2016, 12, e1005717.	2.1	48
67	A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of <i>Mycobacterium tuberculosis</i> . <i>Combinatorial Chemistry and High Throughput Screening</i> , 2016, 19, 855-864.	0.6	8
68	Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. <i>Frontiers in Endocrinology</i> , 2015, 6, 128.	1.5	19
69	Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. <i>PLoS ONE</i> , 2015, 10, e0130796.	1.1	18
70	BioAssay Research Database (BARD): chemical biology and probe-development enabled by structured metadata and result types. <i>Nucleic Acids Research</i> , 2015, 43, D1163-D1170.	6.5	20
71	High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. <i>Stem Cells Translational Medicine</i> , 2015, 4, 800-808.	1.6	70
72	Small Molecule, NSC95397, Inhibits the CtBP1-Protein Partner Interaction and CtBP1-Mediated Transcriptional Repression. <i>Journal of Biomolecular Screening</i> , 2015, 20, 663-672.	2.6	29

#	ARTICLE	IF	CITATIONS
73	Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 811-820.	2.2	20
74	High-Throughput Viability Assay Using an Autonomously Bioluminescent Cell Line with a Bacterial Lux Reporter. Journal of the Association for Laboratory Automation, 2015, 20, 164-174.	2.8	21
75	Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1373-81.	3.3	170
76	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	5.8	118
77	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	1.9	9
78	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
79	Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs. Science Translational Medicine, 2014, 6, 240ra73.	5.8	94
80	High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human Molecular Genetics, 2014, 23, 1551-1562.	1.4	69
81	An Overview of the Challenges in Designing, Integrating, and Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and Disciplines. Journal of Biomolecular Screening, 2014, 19, 614-627.	2.6	22
82	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research, 2014, 42, 6591-6602.	6.5	46
83	Discovery, Optimization, and Characterization of Novel D <sub>2</sub> Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463.	2.9	27
84	Discovery of Novel Antigiardiasis Drug Candidates. Antimicrobial Agents and Chemotherapy, 2014, 58, 7303-7311.	1.4	33
85	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	1.4	30
86	Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening. Journal of Computer-Aided Molecular Design, 2014, 28, 765-778.	1.3	14
87	Discovery and Characterization of a G Protein-Biased Agonist That Inhibits $\beta$ -Arrestin Recruitment to the D2 Dopamine Receptor. Molecular Pharmacology, 2014, 86, 96-105.	1.0	74
88	Allosteric Inhibitors of the Eya2 Phosphatase Are Selective and Inhibit Eya2-mediated Cell Migration. Journal of Biological Chemistry, 2014, 289, 16349-16361.	1.6	46
89	Chemical signatures and new drug targets for gametocytocidal drug development. Scientific Reports, 2014, 4, 3743.	1.6	89
90	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. PLoS ONE, 2014, 9, e90766.	1.1	16

#	ARTICLE	IF	CITATIONS
91	High-Throughput Screening for Modulators of the D2 Dopamine Receptor Yields Unique and Selective Pharmacological Chemotypes. , 2014, , 115.		0
92	Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications, 2013, 4, 2044.	5.8	76
93	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications, 2013, 4, 1953.	5.8	54
94	Structure-Activity Relationship of Imidazopyridinium Analogues as Antagonists of Neuropeptide S Receptor. Journal of Medicinal Chemistry, 2013, 56, 9045-9056.	2.9	18
95	Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer Cell, 2013, 24, 90-104.	7.7	168
96	A TRP Channel in the Lysosome Regulates Large Particle Phagocytosis via Focal Exocytosis. Developmental Cell, 2013, 26, 511-524.	3.1	244
97	A high-throughput screening assay using Krabbe disease patient cells. Analytical Biochemistry, 2013, 434, 15-25.	1.1	26
98	A Novel Brain Penetrant NPS Receptor Antagonist, NCGC00185684, Blocks Alcohol-Induced ERK-Phosphorylation in the Central Amygdala and Decreases Operant Alcohol Self-Administration in Rats. Journal of Neuroscience, 2013, 33, 10132-10142.	1.7	27
99	Inhibitors of the Yersinia protein tyrosine phosphatase through high throughput and virtual screening approaches. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1056-1062.	1.0	12
100	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. Journal of Biomolecular Screening, 2013, 18, 670-677.	2.6	27
101	Î-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.. Journal of Biological Chemistry, 2013, 288, 296.	1.6	0
102	Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. Journal of Biomolecular Screening, 2013, 18, 85-96.	2.6	33
103	Inhibition of Ceramide Metabolism Sensitizes Human Leukemia Cells to Inhibition of BCL2-Like Proteins. PLoS ONE, 2013, 8, e54525.	1.1	40
104	Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens. PLoS ONE, 2013, 8, e70506.	1.1	23
105	Î-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. Journal of Biological Chemistry, 2012, 287, 39349-39360.	1.6	107
106	Non-iminosugar glucocerebrosidase small molecule chaperones. MedChemComm, 2012, 3, 56-60.	3.5	22
107	Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-EBF2 interaction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14592-14597.	3.3	108
108	Discovery of a Novel Noniminosugar Acid Î Glucosidase Chaperone Series. Journal of Medicinal Chemistry, 2012, 55, 7546-7559.	2.9	27

#	ARTICLE	IF	CITATIONS
109	Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. <i>Nature Chemical Biology</i> , 2012, 8, 839-847.	3.9	614
110	Selecting, Acquiring, and Using Small Molecule Libraries for High-Throughput Screening. <i>Current Protocols in Chemical Biology</i> , 2012, 4, 177-191.	1.7	57
111	Discovery, Structure-Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5734-5748.	2.9	113
112	A high-throughput sphingomyelinase assay using natural substrate. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 407-414.	1.9	7
113	A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 731-739.	1.9	31
114	Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 1889-1898.	1.9	49
115	Dealing with the Data Deluge: Handling the Multitude of Chemical Biology Data Sources. <i>Current Protocols in Chemical Biology</i> , 2012, 4, 193-209.	1.7	3
116	High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase. <i>PLoS ONE</i> , 2012, 7, e29861.	1.1	62
117	High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. <i>Current Chemical Genomics</i> , 2012, 6, 79-86.	2.0	22
118	A Homogenous Luminescence Assay Reveals Novel Inhibitors for Giardia Lamblia Carbamate Kinase. <i>Current Chemical Genomics</i> , 2012, 6, 93-102.	2.0	16
119	The synthesis and evaluation of dihydroquinazolin-4-ones and quinazolin-4-ones as thyroid stimulating hormone receptor agonists. <i>MedChemComm</i> , 2011, 2, 1016.	3.5	9
120	Discovery, Synthesis, and Biological Evaluation of Novel SMN Protein Modulators. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6215-6233.	2.9	38
121	Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1033-1058.	2.9	59
122	Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease. <i>PLoS ONE</i> , 2011, 6, e29504.	1.1	11
123	Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. <i>Toxicology and Applied Pharmacology</i> , 2011, 252, 250-258.	1.3	34
124	The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. <i>Science Translational Medicine</i> , 2011, 3, 80ps16.	5.8	359
125	High-Throughput <i>Giardia lamblia</i> Viability Assay Using Bioluminescent ATP Content Measurements. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 667-675.	1.4	43
126	Evaluation of Substituted <i>N,N</i> -Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1048-1055.	2.9	135



#	ARTICLE	IF	CITATIONS
127	Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3387-3393.	1.0	112
128	Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 1880-1897.	2.6	24
129	High Throughput Screening for Inhibitors of Alpha-Galactosidase. <i>Current Chemical Genomics</i> , 2010, 4, 67-73.	2.0	16
130	Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines As Antagonists of the Neuropeptide S Receptor. <i>ACS Chemical Neuroscience</i> , 2010, 1, 559-574.	1.7	25
131	A Multiplex Calcium Assay for Identification of GPCR Agonists and Antagonists. <i>Assay and Drug Development Technologies</i> , 2010, 8, 362-374.	0.6	29
132	Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 2412-2417.	3.3	52
133	Dose-Response Modeling of High-Throughput Screening Data. <i>Journal of Biomolecular Screening</i> , 2009, 14, 1216-1227.	2.6	22
134	The Pilot Phase of the NIH Chemical Genomics Center. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1181-1193.	1.0	28
135	An AlphaScreen <sup>®</sup> -Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction. <i>Journal of Biomolecular Screening</i> , 2009, 14, 273-281.	2.6	47
136	Weighted Feature Significance: A Simple, Interpretable Model of Compound Toxicity Based on the Statistical Enrichment of Structural Features. <i>Toxicological Sciences</i> , 2009, 112, 385-393.	1.4	33
137	Monitoring Compound Integrity With Cytochrome P450 Assays and qHTS. <i>Journal of Biomolecular Screening</i> , 2009, 14, 538-546.	2.6	24
138	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12471-12476.	3.3	102
139	Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. <i>Cancer Research</i> , 2009, 69, 6556-6564.	0.4	105
140	Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 394, 1903-1909.	1.9	11
141	Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. <i>Nature Biotechnology</i> , 2009, 27, 1050-1055.	9.4	154
142	Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5139-5145.	1.4	33
143	A new resorufin-based $\beta$ -glucosidase assay for high-throughput screening. <i>Analytical Biochemistry</i> , 2009, 390, 79-84.	1.1	23
144	A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. <i>Analytical Biochemistry</i> , 2009, 394, 30-38.	1.1	62

#	ARTICLE	IF	CITATIONS
145	A Basis for Reduced Chemical Library Inhibition of Firefly Luciferase Obtained from Directed Evolution. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1450-1458.	2.9	70
146	A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries. <i>Molecular BioSystems</i> , 2009, 5, 1039.	2.9	14
147	Identification of a potent new chemotype for the selective inhibition of PDE4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1297-1303.	1.0	22
148	Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NF $\kappa$ B activity within two separate high-throughput screens of NF $\kappa$ B activation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 329-335.	1.0	20
149	Characterization of Diversity in Toxicity Mechanism Using in Vitro Cytotoxicity Assays in Quantitative High Throughput Screening. <i>Chemical Research in Toxicology</i> , 2008, 21, 659-667.	1.7	70
150	Quantitative High-Throughput Screening Using a Live-Cell cAMP Assay Identifies Small-Molecule Agonists of the TSH Receptor. <i>Journal of Biomolecular Screening</i> , 2008, 13, 120-127.	2.6	59
151	Fluorescence Spectroscopic Profiling of Compound Libraries. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2363-2371.	2.9	247
152	Characterization of Chemical Libraries for Luciferase Inhibitory Activity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2372-2386.	2.9	180
153	A Cell-Based PDE4 Assay in 1536-Well Plate Format for High-Throughput Screening. <i>Journal of Biomolecular Screening</i> , 2008, 13, 609-618.	2.6	21
154	Compound Cytotoxicity Profiling Using Quantitative High-Throughput Screening. <i>Environmental Health Perspectives</i> , 2008, 116, 284-291.	2.8	232
155	COPI Complex Is a Regulator of Lipid Homeostasis. <i>PLoS Biology</i> , 2008, 6, e292.	2.6	293
156	Comparison on Functional Assays for Gq-Coupled GPCRs by Measuring Inositol Monophosphate-1 and Intracellular Calcium in 1536-Well Plate Format. <i>Current Chemical Genomics</i> , 2008, 1, 70-78.	2.0	32
157	A Cell-Based Assay for $\text{I}\kappa\text{B}\alpha$ Stabilization Using A Two-Color Dual Luciferase-Based Sensor. <i>Assay and Drug Development Technologies</i> , 2007, 5, 85-104.	0.6	31
158	Kinase Patent Space Visualization Using Chemical Replacements. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2103-2109.	2.9	47
159	A two-dimensional model of water: Solvation of nonpolar solutes. <i>Journal of Chemical Physics</i> , 2002, 116, 723-729.	1.2	64
160	A View of the Hydrophobic Effect. <i>Journal of Physical Chemistry B</i> , 2002, 106, 521-533.	1.2	816
161	How Ions Affect the Structure of Water. <i>Journal of the American Chemical Society</i> , 2002, 124, 12302-12311.	6.6	685
162	Potential of mean force between two hydrophobic solutes in water. <i>Biophysical Chemistry</i> , 2002, 101-102, 295-307.	1.5	60

#	ARTICLE	IF	CITATIONS
163	Response to "Comment on 'The Mechanism of Hydrophobic Solvation Depends on Solute Radius', J. Phys. Chem. B 2000, 104, 1326". Journal of Physical Chemistry B, 2001, 105, 2082-2083.	1.2	6
164	The Mechanism of Hydrophobic Solvation Depends on Solute Radius. Journal of Physical Chemistry B, 2000, 104, 1326-1331.	1.2	193
165	A two-dimensional model of water: Theory and computer simulations. Journal of Chemical Physics, 2000, 112, 2843-2848.	1.2	71